SARS-CoV-2 seroprevalence and determinants of infection in young adults: a population-based seroepidemiological study.
COVID-19
SARS-CoV-2 antibodies
Seroprevalence
Young adults
Journal
Public health
ISSN: 1476-5616
Titre abrégé: Public Health
Pays: Netherlands
ID NLM: 0376507
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
10
01
2022
revised:
18
02
2022
accepted:
15
03
2022
pubmed:
2
5
2022
medline:
22
6
2022
entrez:
1
5
2022
Statut:
ppublish
Résumé
Most SARS-CoV-2 seroprevalence studies have focussed on adults and high-risk populations, and little is known about young adults. The objective of the present study was to provide evidence on the SARS-CoV-2 seroprevalence among young adults in Germany and to explore determinants associated with seropositivity in general and, specifically, with previously undetected infections. This was a population-based SARS-CoV-2 seroprevalence study. In November 2020, a population-based study on SARS-CoV-2 seroprevalence in young adults (aged 18-30 years) was conducted in a large German city. Serum samples were obtained to analyse the SARS-CoV-2 antibody status using the Elecsys Anti-SARS-CoV-2 immunoassay. Descriptive statistics and odds ratios (ORs) of seropositivity and of previously undetected infections in relation to different determinants were calculated. Among 2186 participants, SARS-CoV-2 antibodies were detected in 72 individuals, equalling a test performance-adjusted seroprevalence of 3.1% (95% confidence interval [CI]: 2.4-4.0). Based on reported COVID-19 cases to the public health authority, a moderate underascertainment rate of 1.7 was calculated. Seropositivity was higher among individuals who sought COVID-19-related information from social media (OR: 1.83, 95% CI: 1.2-3.1), and undetected COVID-19 infections were more prevalent among men and those not adhering to social distancing. The results show a substantial underascertainment of SARS-CoV-2 infections among young adults and indicate that seroprevalence is likely to be much higher than the reported COVID-19 prevalence based on confirmed COVID-19 cases in Germany. Preventive efforts should consider the heterogeneity of risk profiles among the young adult population.
Identifiants
pubmed: 35490440
pii: S0033-3506(22)00084-1
doi: 10.1016/j.puhe.2022.03.009
pmc: PMC8940565
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-61Informations de copyright
Copyright © 2022 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
Références
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 Mar;63(3):254-266
pubmed: 32047976
J Am Coll Health. 2021 Jul 09;:1-7
pubmed: 34242539
Nat Commun. 2020 Oct 8;11(1):5064
pubmed: 33033249
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):88-94
pubmed: 33476314
MMWR Morb Mortal Wkly Rep. 2020 Oct 02;69(39):1404-1409
pubmed: 33001872
PLoS One. 2021 Mar 10;16(3):e0242587
pubmed: 33690600
J Allergy Clin Immunol. 2022 Jan;149(1):65-75.e8
pubmed: 34695490
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
J Infect Dis. 2020 Sep 1;222(7):1086-1089
pubmed: 32750135
J Health Monit. 2020 Nov 18;5(Suppl 5):2-16
pubmed: 35146295
Am J Epidemiol. 1978 Jan;107(1):71-6
pubmed: 623091
Euro Surveill. 2020 Nov;25(47):
pubmed: 33243353
Front Psychol. 2021 Jun 17;12:562042
pubmed: 34220597
Commun Med (Lond). 2021;1(1):4
pubmed: 34870284
J Comput Soc Sci. 2020;3(2):271-277
pubmed: 33251373
Thorax. 2020 Dec;75(12):1089-1094
pubmed: 32917840
Science. 2021 Mar 26;371(6536):
pubmed: 33531384
Euro Surveill. 2021 Nov;26(44):
pubmed: 34738514
Sci Rep. 2021 Nov 3;11(1):21612
pubmed: 34732800
J Public Health (Oxf). 2022 Jun 27;44(2):234-245
pubmed: 33200200
Soc Sci Med. 2021 Jan;268:113370
pubmed: 32980677
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
Soc Sci Med. 2021 May;277:113928
pubmed: 33865093
Clin Microbiol Infect. 2021 Apr;27(4):633.e1-633.e7
pubmed: 33253941
PLoS One. 2021 Mar 22;16(3):e0248918
pubmed: 33750984
Lancet Public Health. 2021 Apr;6(4):e202-e209
pubmed: 33556328
Acta Paediatr. 2021 Jul;110(7):2208-2211
pubmed: 33835507
Sci Rep. 2020 Oct 6;10(1):16598
pubmed: 33024152
Lancet. 2020 Jun 27;395(10242):1973-1987
pubmed: 32497510
Nat Commun. 2021 Feb 8;12(1):844
pubmed: 33558507
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):1063-1071
pubmed: 33534090